Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610470 | 0.83 | CXCR2 (0.48) | CXCR2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1496803 | 0.83 | CXCR2 (0.50) | CXCR2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL2443393 | 0.81 | CXCR2 (0.49) | CXCR2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL2343124 | 0.81 | ALDH1A1 (0.62) | CXCR2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL13010896 | 0.77 | CXCR2 (0.55) | CXCR2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL5689275 | 0.69 | NPC1 (0.41) | ALDH1A1KDM4ELMNASMN1; SMN2KMT2A | |
| SCHEMBL1549413 | 0.69 | CXCR2 (0.49) | CXCR2ALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| SCHEMBL1549254 | 0.69 | CXCR2 (0.49) | CXCR2ALDH1A1KDM4ELMNAALOX15 | |
| SCHEMBL5198420 | 0.69 | KDM4E (0.57) | CXCR2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL3242056 | 0.69 | MAPK1 (0.59) | ALDH1A1KDM4ELMNAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264031-B1 | A NOVEL BENZOXAZINE BENZIMIDAZOLE DERIVATIVE, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND A USE THEREOF | DAE WOONG PHARMA (KR) | 2015-04-15 | — | — | EP | disclosed |
| US-8362012-B2 | Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-01-29 | — | — | US | disclosed |
| US-20110086849-A1 | NOVEL BENZOXAZINE BENZIMIDAZOLE DERIVATIVE, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND AUSE THEREOF | DAEWOONG PHARMACEUTICALS CO., LTD. (KR) | 2011-04-14 | — | — | US | disclosed |
| EP-2264031-A2 | A NOVEL BENZOXAZINE BENZIMIDAZOLE DERIVATIVE, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND A USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086849-A1 | NOVEL BENZOXAZINE BENZIMIDAZOLE DERIVATIVE, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND AUSE THEREOF | TRPV1, HRH4, TRPV4 | CXCR2 1573/4885ALDH1A1 333/4885KDM4E 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.